Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02884102 | MMRF Molecular Profiling Protocol | unknown | — | 1,000 | Multiple Myeloma Research FoundationOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT04637763 | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | unknown | Phase 1 | 72 | Caribou Biosciences, Inc.INDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT06532630 | Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies | unknown | Early Phase 1 | 9 | Shanghai First Song Biotechnology Co., LTDINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06832228 | Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL | unknown | N/A | 30 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06530511 | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL | unknown | Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06539169 | FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases | unknown | — | 1,000 | xCuresINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06585124 | Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas(LA-HLH) | unknown | — | 150 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT03225417 | Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | unknown | Phase 1 / Phase 2 | 142 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT05333302 | Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | unknown | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05914662 | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM(ZBR) | unknown | Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04097067 | ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | unknown | N/A | 83 | University Hospital MuensterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT00877214 | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas(MAINTAIN) | unknown | Phase 3 | 1,272 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05452668 | Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients | unknown | N/A | 51 | Children's Cancer Hospital Egypt 57357OTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05501899 | Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 20 | Children's Hospital of Orange CountyOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06149169 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | unknown | Phase 2 | 10 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05873322 | Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma | unknown | — | 100 | Aarhus University HospitalOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT04682808 | A Study of FCN-338 in Patients With Chronic CLL/SLL | unknown | Phase 1 | 99 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04914741 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)(COALITION) | unknown | Phase 1 / Phase 2 | 80 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06161896 | Characterization and Clinical Impact of the Gut Microbiota in Lymphoma | unknown | — | 200 | Lars Møller PedersenOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05749549 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | unknown | Phase 1 / Phase 2 | 191 | Shanghai Blueray Biopharma Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06392581 | Observational Study on Invasive Fungal Infection Incidence in Ph-neg Acute Lymphoblastic Leukemia Patients(ALL-IFI) | unknown | — | 150 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06468267 | RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. | unknown | Phase 2 | 50 | Xianmin Song, MDOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06509945 | Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL | unknown | N/A | 50 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05190653 | Early Integration of Palliative and Supportive Care in Cellular Therapy(PALS_CT) | unknown | N/A | 152 | Alberta Health Services, CalgaryOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03244176 | Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study(AvR-CHOP) | unknown | Early Phase 1 | 28 | Austin HealthOTHER_GOV | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06427330 | Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia | unknown | Phase 2 | 21 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT05842785 | TSN222 in Subjects With Advanced Solid Tumors or Lymphomas | unknown | Phase 1 / Phase 2 | 162 | Tyligand Bioscience (Shanghai) LimitedINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT05921812 | Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma Patients | unknown | — | 70 | Sohag UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06512272 | Video-recOrded hospItal dischaRge (VOIR)(VOIR) | unknown | N/A | 60 | Anglia Ruskin UniversityOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06508684 | Current Status of BTKi Treatment for CLL/SLL in China | unknown | — | 1,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06058858 | Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis(CMV CAR-T) | unknown | — | 250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06503094 | CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors | unknown | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503211 | On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma | unknown | Phase 1 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06461091 | the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leukemia(TMI) | unknown | — | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT06497452 | A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.(GLOFTST) | unknown | — | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT01231269 | Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma | unknown | N/A | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06492629 | Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06489184 | The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China | unknown | — | 490 | Peking University People's HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06482281 | COVID-19 and Childhood Cancer | unknown | — | 100,000 | Karolinska InstitutetOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT01346020 | Genomic Analysis of Patients With Chronic Lymphocytic Leukemia | unknown | — | 53 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06478381 | L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma | unknown | Phase 1 | 22 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04778579 | Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy(CART19-BE-02) | unknown | Phase 2 | 50 | Sara V. LatorreOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03293173 | Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis(Bio-CHIC) | unknown | Phase 2 | 120 | Nordic Lymphoma GroupNETWORK | 4 | Jun 21, 2024 | clinicaltrials |
| NCT03942224 | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma(DeRIVE) | unknown | Phase 2 | 49 | Emory UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05371392 | Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia | unknown | — | 80 | Sohag UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05422027 | Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 42 | Xia ZhongjunOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05422066 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 50 | Li ZhimingOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06460766 | Validity and Reliability of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity Questionnaire | unknown | — | 70 | Istanbul University - CerrahpasaOTHER | 1 | Jun 14, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 6, 2025source: clinicaltrials